Related Experiment Video

Updated: Oct 7, 2025

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.3K

Therapeutic opportunities for senolysis in cardiovascular disease

Mark Sweeney1,2,3, Stuart A Cook1,2, Jesús Gil1,2

  • 1MRC London Institute of Medical Sciences (LMS), London, UK.

The FEBS Journal
|January 11, 2022
PubMed

Insights

Cellular senescence, a process of aging cells, contributes to cardiovascular diseases like heart failure. Senolytic therapies targeting these senescent cells show promise for managing age-related heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Cellular Aging
  • Gerontology

Background:

  • Cellular senescence's role in cardiovascular disease has been historically underappreciated.
  • Challenges exist in defining senescence in non-dividing cells like cardiomyocytes.
  • Senescent-like changes and the senescence-associated secretory phenotype (SASP) are now recognized in cardiovascular cells.

Purpose of the Study:

  • To review the involvement of senescent cells in the cardiovascular system.
  • To highlight the contribution of senescence to common cardiovascular diseases.
  • To discuss the potential of senolytic therapies for cardiovascular disease management.

Main Methods:

  • Literature review of cellular senescence in the cardiovascular system.
  • Analysis of studies on senescent cells in cardiomyocytes, fibroblasts, and vascular smooth muscle cells.
  • Examination of emerging senolytic therapies and their application in cardiovascular diseases.

Main Results:

  • Senescence occurs in both post-mitotic (cardiomyocytes) and replicating cardiovascular cells (fibroblasts, smooth muscle cells).
  • Senescent cells, via SASP, contribute to the pathogenesis of age-related cardiovascular diseases.
  • Senolytic therapies offer a novel approach to target senescent cells in cardiovascular conditions.

Conclusions:

  • Cellular senescence is a significant factor in age-related cardiovascular diseases.
  • Senolytics represent a promising therapeutic strategy, but further research into senescence biology is needed.
  • Understanding senescence mechanisms is crucial for realizing the full potential of senolytics in cardiovascular medicine.
Keywords:
atherosclerosiscardiovascularheart failurepulmonary hypertensionsenescencesenolytics

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

367
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
551
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
43
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
61
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
698
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
465
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
749